AVXL

Company Overview — What Does ANAVEX LIFE SCIENCES CORP. Do?

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York. ANAVEX LIFE SCIENCES CORP. (AVXL) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Christopher U. Missling and employs approximately 40 people, headquartered in New York, New York. With a market capitalization of $287M, AVXL is one of the notable companies in the Healthcare sector.

ANAVEX LIFE SCIENCES CORP. (AVXL) Stock Rating — Avoid (April 2026)

As of April 2026, ANAVEX LIFE SCIENCES CORP. receives a Avoid rating with a composite score of 28.0/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.AVXL ranks #4,192 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, ANAVEX LIFE SCIENCES CORP. ranks #748 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

AVXL Stock Price and 52-Week Range

ANAVEX LIFE SCIENCES CORP. (AVXL) currently trades at $3.01. The stock lost $0.04 (1.3%) in the most recent trading session. The 52-week high for AVXL is $13.99, which means the stock is currently trading -78.5% from its annual peak. The 52-week low is $2.86, putting the stock 5.2% above its annual trough. Recent trading volume was 1.0M shares, reflecting moderate market activity.

Is AVXL Overvalued or Undervalued? — Valuation Analysis

ANAVEX LIFE SCIENCES CORP. (AVXL) carries a value factor score of 32/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 2.25x, versus the sector average of 2.75x. The price-to-sales ratio is 59.99x, compared to 1.66x for the average Healthcare stock.

At current multiples, ANAVEX LIFE SCIENCES CORP. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

ANAVEX LIFE SCIENCES CORP. Profitability — ROE, Margins, and Quality Score

ANAVEX LIFE SCIENCES CORP. (AVXL) earns a quality factor score of 27/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -33.4%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -31.8% versus the sector average of -33.1%.

The operating margin is -995.7% (sector: -66.1%). Net profit margin stands at -888.1%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -39.9% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

AVXL Debt, Balance Sheet, and Financial Health

ANAVEX LIFE SCIENCES CORP. has a debt-to-equity ratio of 5.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 20.87x, indicating strong short-term liquidity.

AVXL has a beta of 1.22, meaning it is more volatile than the broader market — a $10,000 investment in AVXL would be expected to move 22.2% more than the S&P 500 on any given day. The stability factor score for ANAVEX LIFE SCIENCES CORP. is 22/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

ANAVEX LIFE SCIENCES CORP. Revenue and Earnings History — Quarterly Trend

In TTM 2026, ANAVEX LIFE SCIENCES CORP. reported revenue of $5M and earnings per share (EPS) of $-0.06. Net income for the quarter was $-42M. Operating income came in at $-47M.

In Q1 2026, ANAVEX LIFE SCIENCES CORP. reported revenue of $1M and earnings per share (EPS) of $-0.06. Net income for the quarter was $-6M. Revenue grew -22.6% year-over-year compared to Q1 2025. Operating income came in at $-7M.

In FY 2025, ANAVEX LIFE SCIENCES CORP. reported revenue of $5M and earnings per share (EPS) of $-0.54. Net income for the quarter was $-46M. Revenue grew -36.1% year-over-year compared to FY 2024. Operating income came in at $-51M.

In Q3 2025, ANAVEX LIFE SCIENCES CORP. reported revenue of $1M and earnings per share (EPS) of $-0.16. Net income for the quarter was $-13M. Revenue grew -40.1% year-over-year compared to Q3 2024. Operating income came in at $-14M.

Over the past 8 quarters, ANAVEX LIFE SCIENCES CORP. has demonstrated a growth trajectory, with revenue expanding from $2M to $5M. Investors analyzing AVXL stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

AVXL Dividend Yield and Income Analysis

ANAVEX LIFE SCIENCES CORP. (AVXL) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

AVXL Momentum and Technical Analysis Profile

ANAVEX LIFE SCIENCES CORP. (AVXL) has a momentum factor score of 15/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 39/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 53/100 reflects moderate short selling activity.

AVXL vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, ANAVEX LIFE SCIENCES CORP. (AVXL) ranks #748 out of 838 stocks based on the Blank Capital composite score. This places AVXL in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing AVXL against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full AVXL vs S&P 500 (SPY) comparison to assess how ANAVEX LIFE SCIENCES CORP. stacks up against the broader market across all factor dimensions.

AVXL Next Earnings Date

No upcoming earnings date has been announced for ANAVEX LIFE SCIENCES CORP. (AVXL) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy AVXL? — Investment Thesis Summary

The quantitative profile for ANAVEX LIFE SCIENCES CORP. suggests caution. The quality score of 27/100 flags below-average profitability. The value score of 32/100 indicates premium valuation. Momentum is weak at 15/100, a headwind for near-term performance. High volatility (stability score 22/100) increases portfolio risk.

In summary, ANAVEX LIFE SCIENCES CORP. (AVXL) earns a Avoid rating with a composite score of 28.0/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on AVXL stock.

Related Resources for AVXL Investors

Explore more research and tools: AVXL vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare AVXL head-to-head with peers: AVXL vs AZN, AVXL vs SLGL, AVXL vs VMD.